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Haemoglobinopathies such as thalassaemia and sickle cell disease present a major health burden. Currently, the main forms of
treatment for these diseases are packed red blood cell transfusions and the administration of drugs which act to nonspeciﬁcally
reactivatetheproductionoffoetalhaemoglobin.Thesetreatmentsareongoingthroughoutthelifeofthepatientandareassociated
with a number of risks, such as limitations in available blood for transfusion, infections, iron overload, immune rejection, and side
eﬀects associated with the drug treatments. The ﬁeld of cellular reprogramming has advanced signiﬁcantly in the last few years and
has recently culminated in the successful production of erythrocytes in culture. This paper will discuss cellular reprogramming
and its potential relevance to the treatment of haemoglobinopathies.
1. Introduction:Globin GeneRegulation and
Haemoglobinopathies
The various blood cell lineages in mammals arise from a
multipotent haematopoietic stem cell via particular diﬀer-
entiation pathways. One of these pathways, erythropoiesis,
leads to the production of red blood cells (RBCs), which
transport oxygen and carbon dioxide around the body by
meansoftheintracellularmetalloproteinhaemoglobin(Hb).
Hbisatetramer,consistingoftwoα-globinandtwoβ-globin
subunits. In mammals, these globin chains are encoded by
two gene loci: the α-globin locus and the β-globin locus. In
humans, the α-globin locus consists of the embryonic ζ-a n d
adult α-globin genes, and the β-globin locus comprises the
embryonic ε-, foetal γG-a n dγA-,a n da d u l tδ-a n dβ-globin
genes [1, 2]. The globin genes expressed from these loci diﬀer
from embryonic to adult erythropoiesis in order to meet
varying oxygen demands and facilitate placental transfer of
o x y g e nf r o mm o t h e rt oe m b r y o[ 3].
There are a number of severe diseases caused by the
disruption of adult globin genes, including thalassaemias
and certain types of anaemia. According to the World Health
Organisation, approximately 5% of the world’s population
carry genes involved in Hb disorders, and as such, they
present an enormous health burden. Thalassaemia is caused
by a reduction or abolition of the expression of one or more
globin genes, resulting in an imbalance of α- and β-globin
chains in red blood cells and consequent anaemia [1, 4].
Sickle cell anaemia is another prevalent haemoglobinopathy
and is caused by a mutation in the adult β-globin gene
which generates a single glutamic acid to valine amino acid
substitution. This mutation leads to the polymerisation
of globins in venous circulation [5, 6], which can trigger
a rigid and sickled cell phenotype [7, 8] and results in a
number of acute conditions such as vaso-occlusion, splenic
sequestration, and haemolytic anaemia [9].
There are currently a number of treatments available
for patients suﬀering from thalassaemia and sickle cell
anaemia. The most common is packed red blood cell
transfusion,butthisisassociatedwithanumberofproblems,
such as suﬃciency of supply, bacterial and viral infection,
biochemical and biomechanical changes during storage (red
blood cell storage lesions), and the risk of immune rejection
from the patient [10, 11]. Furthermore, blood transfusions
are ongoing throughout a patient’s life and often lead to a
potentially fatal buildup of iron and associated reduction in
organ activity.
Another potential therapeutic option involves the reac-
tivation of foetal γ-globin expression in adult patients.
Residual production of foetal γ-globin persists naturally2 International Journal of Cell Biology
throughout life, and levels vary between individuals [12, 13].
Thispersistentexpressionallowstwoγ-globinchainstocom-
bine with two adultα-globin chains to form what is known as
foetal Hb (HbF). As only the adult β-globin gene is mutated
in sickle cell anaemia, aﬀected infants are protected from
severe symptoms until they reach several months of age, due
to the large amount of HbF still in circulation at birth [14].
Furthermore, patients who have inherited alleles associated
with increased levels of HbF, known as hereditary persistence
of foetal Hb (HPFH), are protected into adulthood [15].
Similarly, a more asymptomatic disease phenotype has also
been shown in patients with β-thalassaemia who exhibit
higher levels of HbF [16]. Together, these observations
indicate that increased foetal γ-globin is able to compensate
in part for the loss of adult β-globin function and thus ame-
liorates the symptoms of certain adult haemoglobinopathies.
Accordingly,anumberofdrugtreatmentsforβ-thalassaemia
and sickle cell disease, for instance, 5-azacitidine, hydrox-
yurea, and butyrate, all act by nonspeciﬁcally reactivating
foetal γ-globin gene expression by various mechanisms. The
eﬀects of these drug treatments are transient and thus
require ongoing administration. There is evidence that long-
term administration of these drugs has chronic side eﬀects,
consistent with their lack of speciﬁcity [8, 17].
As the existing methods of treatment for these haemo-
globinopathies remain inadequate, alternative forms of ther-
apy are currently being sought, and stem cell therapies
should be considered. This paper will discuss progress in
utilising novel cellular reprogramming techniques to treat
RBC diseases.
2.CellularReprogramming
Stem cells, both embryonic and adult, have the ability
to diﬀerentiate into various cell types, making them a
potentially attractive treatment option. Embryonic stem
cells (ESCs) and adult stem cells (ASCs) each have their own
strengths and disadvantages in these strategies. ESCs are
more easily grown in culture and are pluripotent, meaning
thattheyareabletodiﬀerentiateintoanycellofthebody.The
practicality of widespread ESC use for therapeutic purposes,
however, has been questioned due to issues of supply and
ethical and legal considerations. Moreover, these cells carry
the risk of allogeneic immune rejection. ASCs, on the other
hand, overcome some of these problems as they can be
harvested from each individual patient. These cells, however,
oﬀer a diﬀerent set of challenges. They are not abundant
and are diﬃcult to obtain, often being harboured in internal
organs such as the gut and bone marrow. They have proven
diﬃcult to culture in vitro [18], and furthermore, they are
widely believed to be multipotent rather than pluripotent
and are thus only able to diﬀerentiate into certain cell types
[19]. Cellular reprogramming potentially overcomes these
issues and may oﬀer new treatment methods for a range of
diseases, including those of RBCs.
2.1. Classic Cellular Reprogramming. Takahashi and
Yamanaka[20]weretheﬁrsttoshowthatitispossibletotake
diﬀerentiated somatic cells and transform them into cells
with pluripotent potential. They began by identifying a pool
of 24 transcription factors which are important in maintain-
ingstemcelltraitsandusedretroviraltransductiontoexpress
these factors in murine embryonic and adult ﬁbroblasts.
They found that these cells then displayed characteristics and
properties comparable to those of pluripotent ESCs. They
were able to further reﬁne the required transcription factors
by setting up numerous combinations to determine which
were essential to this process and identiﬁed four factors,
Oct4, Sox2, Klf4, and c-Myc, needed to transform a somatic
cell to an induced pluripotent stem cell (iPSC). Takahashi
et al. [21] then applied these four factors to human cells
and transformed neonatal and adult human ﬁbroblasts into
human iPSCs (hiPSCs). This was a valuable subsequent step
as it showed that this process can be reproduced with human
cells and could thus potentially be utilised for stem cell-
basedtherapiesofhumandisease.Severalothertranscription
factor combinations have since been shown to be suﬃcient
to reprogram somatic cells [22–24] and one particular
combination, involving OCT4, SOX2, NANOG, and LIN28,
is particularly eﬃcient and is now widely utilised [25].
Figure 1(a) depicts the process of cellular reprogramming.
There are several potential issues associated with using
iPSCs to treat disease. For example, a number of the
transcriptionfactorsusedtogeneratethesecells,including c-
Myc,Klf4,andLin28,areoncogenes,andtheirmisexpression
can lead to cancer [26–28]. In order for iPSCs to be
diﬀerentiated into a cell type of choice, the retrovirally
transmitted genes need to be switched oﬀ or removed to
reduce the possibility of their inducing tumours [22, 29].
Another potential issue is that the transplantation of any
cells that have not been fully diﬀerentiated from the iPSC
state could lead to the formation of cancerous teratomas.
Any cells remaining which are still in a pluripotent state
couldmultiplyand,withouttheappropriategrowthcontrols,
would have the potential to result in tumours in transplant
patients. To potentially avoid the issue of tumour formation
and uncontrolled proliferation of iPSCs, an alternative
methodology known as transdiﬀerentiation is also being
considered as a potential treatment strategy.
2.2. Transdiﬀerentiation. Transdiﬀerentiation is achieved by
introducing various exogenous factors into a diﬀerentiated
cell, such as a ﬁbroblast, to directly convert it into another
type of diﬀerentiated cell, thereby bypassing the pluripotent
state(Figure 1(b)).Asearlyas1990,Choietal.[30]wer eable
to convert various cells types, including dermal ﬁbroblasts
and chondroblasts, into mononucleated, striated myoblasts
that were indistinguishable from normal myoblasts in vivo.
This was achieved through the expression of the myogenic
regulatory factor MyoD, a transcription factor known to
be involved in the determination of muscle cells. Shortly
after this, another group showed that it was possible to
turn myeloid 416B cells into mast cells through the forced
expression of GATA-2 and GATA-3, two transcription factors
which play important roles in haematopoiesis [31]. Halder
et al.[32]investigatedtheeﬀectsofectopicallyexpressingthe
geneeyeless(ey),anorthologueofthemammalianPax6 gene,International Journal of Cell Biology 3
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Figure 1: Diagrammatic representation of cellular reprogramming compared to transdiﬀerentiation in the development of erythrocytes.
(a) Fibroblasts cells can be reprogrammed into pluripotent cells through the introduction of various exogenous factors. From this induced
pluripotent state, these cells can be either cultured with various cytokines supporting erythrocyte diﬀerentiation and growth, for instance,
IL-3, IL-6, and Erythropoietin (Epo) or cultured with OP9 bone marrow stroma cells to diﬀerentiate into erythrocytes. (b) Fibroblasts
cells can be reprogrammed directly into erythrocytes through the introduction of Oct4 and culturing with Epo in conjunction with other
haematopoietic cytokines.
in Drosophila and found that eye structures formed in places
such as the wings and legs.
Since Takahashi and Yamanaka’s pioneering studies in
cellular reprogramming, the ﬁeld of transdiﬀerentiation has
advanced considerably. Zhou et al. [33] investigated the
eﬀects of expressing Ngn3, Pdx1, and Mafa, transcription
factors involved in β-cell diﬀerentiation, on exocrine cells
of the adult pancreas. They found that the coexpression
of these factors was able to convert the exocrine cells into
β-cells. The induced β-cells were identical to endogenous
β-cells in morphology and showed similar expression of
genes associated with β-cell function. These cells can also
rescue the phenotype of hyperglycaemia, as they are able
to secrete insulin and remodel surrounding vasculature.
In other work, Vierbuchen et al. [34] utilised the neural-
speciﬁc transcription factors, Ascl1, Brn2, and Myt1l, to
rapidly convert both murine embryonic ﬁbroblastsand adult
ﬁbroblasts directly into functional neurons. These induced
neuronal cells express neuron-speciﬁc proteins, generate
action potentials, and form functional synapses. A further
advance has shown that it is also possible to transdiﬀeren-
tiate ﬁbroblasts into functional neural progenitor cells by
transient induction of Oct4, Sox2, Klf4, and c-Myc in cells
cultured in a deﬁned neural reprogramming medium [35].
This process bypassed the generation of iPSCs and gave
rise to multipotent progenitors with the capacity to expand
and diﬀerentiate into a number of neural lineages. All of
these experiments indicate that it is possible to direct a
diﬀerentiated cell to another cell fate through the application
of extragenic factors.
3.CellularReprogrammingasaPotential
Treatment for Anaemia
Advances in cellular reprogramming have raised the attrac-
tive possibility that this technology could be utilised to
generate a limitless source of immune-matched, pathogen-
free erythrocytes for transfusion. Eﬀorts were thus made
to produce mature erythroid cells from hiPSCs in culture.
An initial study by Feng et al. [28]r e v e a l e ds o m ep r a c t i c a l
diﬃculties.TheyfoundthathiPSCsarecapableofgenerating
haematopoietic cells with phenotypic and morphological
characteristicssimilar to those derived fromhESCs; however,
these hiPSC-derived cells exhibited a dramatically reduced
capacity (by greater than 1000-fold) to generate erythroid
cells.
A subsequent study by Lapillone et al., however, showed
that it was indeed possible to produce signiﬁcant numbers
of mature erythroid cells from hiPSCs in vitro [36]. This
group employed the methods outlined by Thomson’s group
[25] using OCT4, SOX2, NANOG, and LIN28 to convert
ﬁbroblasts to hiPSCs. They then cultured these cells in
medium containing the cytokines SCF, TPO, FLT3 ligand,
rhu BMP4, rhu VEGF-A165, IL-3, IL-6, and erythropoietin
(Epo). These culture conditions were optimised to obtain
embryoid bodies that display early erythroid commitment.
They analysed the expression proﬁles of these cells over 20
days of culture and found that pluripotent stem cell markers
decreased whilst the erythroid markers CD36, CD235a,
and CD71 increased. Cells at day 20 were found to have
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cocktails of cytokines comprising SCF, IL-3, and/or Epo.
Erythroidmaturationwasachievedafteranother25daysand
was conﬁrmed by morphological examination and by ﬂow
cytometricanalysisoferythroidmarkers(CD235ahi,CD71hi,
and CD36lo). Furthermore, these erythroid cells were able to
enucleate, albeit with reduced capacity compared to hESC-
derived erythroid cells, and were found to express functional
Hb (predominantly HbF). These hiPSC-derived erythroid
cells were compared to those diﬀerentiated from hESCs, and
no signiﬁcant diﬀerences were detected in terms of erythroid
commitment, expression of erythroid markers, and type and
functionality of Hb.
The study by Lapillone et al. revealed that while func-
tional RBCs could be generated from hiPSCs, when com-
pared to hESCs, hiPSCs were shown to have reduced (ap-
proximately 8-fold) ampliﬁcation potential in producing
mature erythroid cells. A recent study has set out to deter-
mine whether this reduced eﬃciency is an intrinsic property
of hiPSCs, or whether it can be increased by altered culture
conditions[37].Thisstudyshowednotonlythatitispossible
to generate RBCs from hiPSCs with similar eﬃciency to
hESCs, but also that these cells can be diﬀerentiated from
hiPSCs generated using episomal vectors, obviating the need
for potentially deleterious retroviral transfection. This group
cultured hiPSCs derived from human ﬁbroblasts with the
OP9 bone marrow stroma line to induce hematopoietic
diﬀerentiation and followed this with selective expansion of
erythroid cells in serum-free media with cytokines support-
ing RBC diﬀerentiation. The erythroid cultures established
in this study consisted of a pure population of CD235a+
CD45− leukocyte-free RBCs which had robust expansion
capabilities, as well as a long lifespan of up to 90 days.
These hiPSC-derived cells can enucleate and were shown
to express foetal γ- and embryonic ε-globin demonstrating
successful reprogramming of the β-globin locus. The results
from this study show that it is possible to produce signiﬁcant
numbers of erythroid cells from ﬁbroblast-derived hiPSCs,
and that thus cellular reprogramming could contribute to
the treatment of haemoglobinopathies. Furthermore, since
these RBCs are generated from transgene-free hiPSCs, they
circumvent problems associated with genomic integration
and undesired reactivation of reprogramming factors.
Another recent study has shown that it is possible to use
transdiﬀerentiation to produce haematopoietic cell lineages,
including mature erythrocytes [38]. In this work, Szabo et al.
transduced human dermal ﬁbroblasts with OCT4 alone and
showed that these cells then express the panhaematopoietic
marker CD45 but lack the pluripotency marker Tra-1-60.
They then cultured these cells in a haematopoietic cytokine
cocktail containing SCF, G-CSF, FLT3LG, IL-3, IL-6, and
BMP-4 supplemented with Epo and observed an emergence
of cells expressing adult β-globin protein and the red blood
cell marker Glycophorin-A. Moreover, these erythroid cells
were able to mature in culture and underwent enucleation.
In addition, the authors noted that these erythroid cells
express adult rather than embryonic globins, unlike cells
derived from human pluripotent stem cells [39, 40], perhaps
suggesting that they have indeed been transdiﬀerentiated
from adult ﬁbroblasts, bypassing the hiPSC stage. As the
techniques used in this study avoid the pluripotent state as
well as have a high yield, expansion capacity, and clinical
feasibility, this strategy could provide a reasonable basis for
autologous cell replacement therapies.
These studies demonstrate that it is possible to diﬀerenti-
ate hiPSCs into mature erythrocytes in vitro for transfusions.
In order to utilise these methods to treat RBC diseases
successfully, ﬁbroblasts could potentially be taken from
either a healthy immunomatched individual, or a universal
donor, and be converted to erythrocytes via the hiPSC
state. These cells could then be mass produced in culture
and stored for transfusion. A study has already developed
hiPSCs from an individual with a Bombay phenotype of the
ABO blood group system, where the ABH antigen is not
expressed on RBCs, and blood can be donated to anyone
[41]. This group has further demonstrated that it is possible
to diﬀerentiate haematopoietic lineages from these cells
although they have not explicitly shown mature erythrocyte
diﬀerentiation. This possible treatment method circumvents
many of the problems associated with current transfusions,
such as questionable quality, lack of supply, and immune-
rejection. However, issues still remain, such as cost and the
risk of iron overloading.
4.CellularReprogrammingasaPotential
Cure for Anaemia
In order to cure, rather than treat, RBC diseases, healthy
progenitor cells must be transplanted into patients and sub-
sequently repopulate the haematopoietic system. A promis-
ing study has already shown that it is possible to use
reprogrammed cells to treat sickle cell anaemia in mice.
Hanna et al. [42] took cells from the tail tips of a humanized
sickle cell anaemic mouse model, in which the mouse α-
globin genes have been replaced with human α-globin,a n d
the mouse β-globin genes have been replaced with human γA
and βS (sickle) globin genes [43], and through adaptation
of the protocol developed by Takahashi and Yamanaka,
who reprogrammed these cells into iPSCs. Once this was
accomplished,theywereabletocorrectthemutantβS-globin
gene by replacing it with a copy of the wildtype human β-
globin gene through homologous recombination. Following
this, the iPSCs were diﬀerentiated into haematopoietic
progenitors through the ectopic expression of HoxB4, and
by growing in haematopoietic cytokines on an OP9 bone
marrow stroma cell line. These corrected haematopoietic
progenitor cells were transplanted into the sickle mice
after irradiation. This group then carried out extensive
testing to determine whether the treated mice displayed any
further signs of the disease. Firstly, functional correction
was evaluated by electrophoresis for the human β-globin
proteins γA and βS, and they found a signiﬁcant increase
in γA-a n dad e c r e a s ei nβS-globin. Blood counts were also
performed 12 weeks after transplant, which showed that
treatedmicehadincreasedRBCs,Hb,andpackedcellvolume
aswellasreducedreticulocytes,acommonindicatorofsickle
cell disease and severity. Lastly, they examined symptomatic
indicators of sickle cell anaemia such as urine concentration,
body weight, and breathing rate and found that all threeInternational Journal of Cell Biology 5
of these parameters were ameliorated in the treated mice.
This study thus provides an important proof of principle
that cellular reprogramming can be employed to correct
erythroid disorders, albeit in this case, in conjunction with
gene therapy.
5. Conclusions
Normalerythropoiesisisdependentuponthecorrectexpres-
sion of globin genes. Where globin genes are incorrectly
expressed, or are mutated, anaemia or thalassemia results.
Current therapy for these disorders involves packed red
blood cell transfusions, which are limited by supply, risk of
infection, expense, and patient rejection. Drug-based thera-
pies involve the nonspeciﬁc reactivation of foetal globins and
have long-term side eﬀects. In seeking alternative strategies,
recentadvanceshaveshownthatcellularreprogrammingcan
now generate large quantities of red blood cells in culture,
potentially for use in transfusions. Furthermore, these
strategieshavebeensuccessfullycombinedwithgenetherapy
to treat a sickle cell anaemia mouse model, suggesting that
cellular reprogramming will provide a realistic future alter-
native to conventional treatment of haemoglobinopathies.
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